GRANULESstockGranules India Ltd
₹744
▼-0.65%
Open
₹752.85
High
₹759.1
Low
₹736.8
Volume
863.2K
Price chart
Daily close · downsampled 5-year history
2021-06-21 · ₹313.852026-06-18 · ₹746.45
Instrument details
- MB Code
- MBEQU4151
- Type
- stock
- ISIN
- INE101D01020
- BSE
- 532482
- Industry
- Pharmaceuticals & Biotechnology
Latest earnings
Q4FY26 declared
- Quarter
- Mar 2026
- Revenue
- 1470.61 Cr
- Net profit
- 201.57 Cr
- EPS
- 8.23
- YoY revenue
- +22.81%
Price returns
Historical performance
- 1 day
- +0.72%
- 1 month
- -2.58%
- 3 months
- +26.35%
- 1 year
- +50.87%
- 3 years
- +153.51%
- 5 years
- +139.86%
Technicals
Indicator consensus
Bullish
23
Neutral
4
Bearish
19
RSI 26.77(Bullish)
Company documents
Annual reports, concalls, presentations
Concall transcripts
42Investor presentations
86Corporate announcements
216Corporate timeline
Price chart events · 1 year
Dividend
2025-07-31
{"amount":1.5}
Earnings
2025-11-13
{"actualRevenue":12969880000,"estimateRevenue":12198000000,"revenueSurprise":771880000,"revenueSurprisePercent":6.327922610263978,"actualEPS":5.38,"estimateEPS":5.15,"surprise":0.2299999999999995,"surprisePercent":4.466019417475719}
Earnings
2026-04-29
{"actualRevenue":14706080000,"estimateRevenue":14903000000,"revenueSurprise":-196920000,"revenueSurprisePercent":-1.321344695698853,"actualEPS":7.58,"estimateEPS":7.21,"surprise":0.3700000000000001,"surprisePercent":5.131761442441055}
Earnings
2026-01-23
{"actualRevenue":13879400000,"estimateRevenue":12989000000,"revenueSurprise":890400000,"revenueSurprisePercent":6.855031180229425,"actualEPS":6.19,"estimateEPS":6.18,"surprise":0.01000000000000068,"surprisePercent":0.1618122977346388}
Earnings
2025-08-12
{"actualRevenue":12101060000,"estimateRevenue":13169000000,"revenueSurprise":-1067940000,"revenueSurprisePercent":-8.109499582352495,"actualEPS":5.71,"estimateEPS":5.459,"surprise":0.2510000000000003,"surprisePercent":4.597911705440564}
News
2025-12-23
{"description":"Granules India Ltd's board approved raising up to ₹1,760 crore, including ₹1,462.50 crore via convertible warrants and ₹300 crore through equity shares. Additionally, its subsidiary received tentative FDA approval for a key ADHD treatment, potentially worth $172 million.","url":"https://www.cnbctv18.com/market/granules-india-share-price-board-approves-raising-funds-details-here-19799956.htm","sentiment":"Positive","domain":"CNBCTV18"}
News
2025-12-22
{"description":"Granules India has received USFDA approval for its generic ADHD medication, Amphetamine extended-release orally disintegrating tablets, expanding its US portfolio. The market size for this drug is estimated at USD 172 million. This approval supports Granules' strategy in complex generics and CNS therapies.","url":"https://money.rediff.com/news/market/granules-gets-usfda-nod-for-adhd-generic-drug/39034120251222","sentiment":"Positive","domain":"Rediff Money"}
News
2025-09-21
{"description":"Granules India Ltd reported a remarkable 191.40% increase in standalone net profit for the quarter ending September 2025, reaching Rs 120.61 crore compared to Rs 41.39 crore in the same quarter last year, indicating strong financial performance.","url":"https://www.business-standard.com/markets/capital-market-news/granules-india-standalone-net-profit-rises-191-40-in-the-september-2025-quarter-125111400174_1.html","sentiment":"Positive","domain":"Business Standard"}